Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies

OBJECTIVES: China suffers from high burdens of human papillomavirus (HPV) and cervical cancer, whereas the uptake of HPV vaccine remains low. The first Chinese domestic HPV vaccine was released in 2019. However, collective evidence on cost-effectiveness of HPV vaccination in China has yet to be esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wenchuan, Cheng, Xiaoli, Wang, Haitao, Zang, Xiao, Chen, Tingting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655525/
https://www.ncbi.nlm.nih.gov/pubmed/34880019
http://dx.doi.org/10.1136/bmjopen-2021-052682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655525/
https://www.ncbi.nlm.nih.gov/pubmed/34880019
http://dx.doi.org/10.1136/bmjopen-2021-052682

Ejemplares similares